Showing 113 of 113on this page. Filters & sort apply to loaded results; URL updates for sharing.113 of 113 on this page
Full article: Epcoritamab in B-cell malignancies: current status and ...
Epcoritamab (TEPKINLY®) [Acthera]
Bispecific Antibody Research Update: Epcoritamab Receives FDA Priority ...
Lymphoma Australia Epcoritamab - New Treatment for DLBCL
记住所有FDA生物药 | 靶向CD20 x CD3双抗 | Epcoritamab | 弥漫性大B细胞淋巴瘤(DLBCL) - 知乎
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is ...
Epcoritamab - Anwendung, Wirkung, Nebenwirkungen | Gelbe Liste
Therapeutic potential of CD20 x CD3 bispecific antibodies - Medical ...
Thuốc Epcoritamab điều trị u lympho tế bào B và u lympho nang
Epcoritamab (GEN3013) | Anti-CD3/CD20 Antibody | MedChemExpress
Dose escalation of subcutaneous epcoritamab in patients with relapsed ...
Subcutaneous Epcoritamab Brings 82% Overall Response in Patients With R ...
T-cell activation by epcoritamab does not correlate strongly with ...
Epcoritamab Granted Priority Review for Relapsed/Refractory Large B ...
Epcoritamab mediates comparable levels of cytotoxicity in various B-NHL ...
Trial Shows Epcoritamab Combo Effective for Relapsed/Refractory ...
Simulated Exposure of Epcoritamab | Download Scientific Diagram
Lower T-cell activation by epcoritamab in presence of tumor cells with ...
Epcoritamab Gets Label Expansion for Difficult-to-Treat R/R Follicular ...
Epcoritamab
Epcoritamab (GEN3013，艾可瑞妥单抗) - 仅供科研 | 抗CD3/CD20抗体 | MCE
The effective and safe administration of Epcoritamab in relapsed CD19 ...
FDA Approval of Epcoritamab for Relapsed or Refractory Follicular ...
Epcoritamab Delivers High Responses in DLBCL
Epcoritamab Monotherapy Yields Positive Results in Phase 3 R/R DLBCL ...
Epcoritamab and talquetamab near EMA approval in cancer
Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab ...
Full article: Combinability of epcoritamab CD20-targeting T-cell ...
Epcoritamab induces potent anti-tumor activity against malignant B ...
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory ...
FDA Approves Epcoritamab for Two Follicular Lymphoma Indications - The ...
(PDF) Epcoritamab induces potent anti-tumor activity against malignant ...
240 | EPCORITAMAB MONOTHERAPY DEMONSTRATES DEEP AND DURABLE RESPONSES ...
Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed ...
FDA Approves Epcoritamab for Relapsed/Refractory DLBCL
Mechanism of Action - EPKINLY® (epcoritamab-bysp) HCP
Pipeline
$康诺亚-B(02162)$ 创新药周报20230521：Epcoritamab获批，关注CD3×CD20双抗进展原创 ... - 雪球
The wonders of the T-cell: bispecific antibodies in diffuse large B ...
创新“血与蜜之地”：巨头先行，CD20/CD3双抗突破在望 - 知乎
双特异性T细胞衔接器（TCE）-CD3双抗-TCE作用机制/技术平台-德泰生物
Epcoritamab-bysp is approved by FDA for relapsed or refractory diffuse ...
CD20 X CD3双特异抗体格局 近日， Genmab 和艾伯维宣布其靶向CD20xCD3的双特异抗体epcoritamab（GEN3013 ...
Full article: Trial watch: bispecific antibodies for the treatment of ...
FDA批准第2款CD3/CD20双抗：艾伯维/Genmab的Epcoritamab Armstrong 2023年5月19日，艾伯维 ...
创新药周报：Epcoritamab获批，关注CD3×CD20双抗研发进展
Epcoritamab有效率88%，双抗治疗肿瘤时代或将到来|剂量|细胞|其中|方面|淋巴瘤|-健康界
全球获批的10款双抗全梳理|CD20|ORR|CD3|双抗|细胞|抗体|靶向|-健康界
Bispecific antibodies in follicular lymphoma | Haematologica
CD3/CD20 (Epcoritamab) Antibody - Azide and BSA Free (NBP3-44563 ...
新面孔！缓解率61%！新型CD3/CD20双抗Epcoritamab获得美国FDA加速批准_可愈有道
艾伯维/Genmab：CD3/CD20双抗获FDA优先审评资格 Armstrong 2022年11月21日，艾伯维与 Genmab 宣布CD3 ...
Anti-CD20/CD3-Epcoritamab Antibody, 68185-H001 | Sino Biological
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging ...
FDA批准第2款CD3/CD20双抗：艾伯维/Genmab的Epcoritamab医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
AbbVie联手Genmab研发三种双抗，前者支付近40亿美元购买特许权 - 小桔灯网 - IIVD.NET
Intratumoral T-cell composition predicts epcoritamab-based treatment ...
(Epcoritamab) - 药物靶点：CD20 x CD3_在研适应症：纵隔大b细胞淋巴瘤，复发性滤泡性淋巴瘤，难治性滤泡性淋巴瘤_专利 ...
CD20/CD3双抗联合R2方案治疗初治滤泡性淋巴瘤，总缓解率高达95% - 知乎
艾伯维重磅新型CD3/CD20双抗Epkinly（epcoritamab）获美FDA加速批准！-印塔健康官网
(PDF) Semimechanistic Physiologically Based Pharmacokinetic ...
艾伯维CD3/CD20双抗Epcoritamab在美获批滤泡性淋巴瘤适应症
2024年6月26日FDA加速批准CD3/CD20双特异性抗体疗法Epcoritamab-bysp(艾可瑞妥单抗、Epkinly)用于治疗治疗 ...
【柳叶刀血液学】CD3/CD20双抗Epcoritamab治疗R/R FL的2期研究结果-MedSci.cn
艾可瑞妥单抗(Epcoritamab) - 药物靶点：CD20 x CD3_在研适应症：大B细胞淋巴瘤，复发性 3b 级滤泡性淋巴瘤，纵隔大b ...
Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic ...
全球获批的10款双抗全梳理 近期，艾伯维/ Genmab 的CD3/CD20双抗获批上市，用于治疗复发难治性弥漫大B细胞淋巴瘤（R/R ...
艾伯维重磅新型CD3/CD20双抗Epkinly（epcoritamab）获美FDA加速批准！_细胞_患者_治疗
RxTROSPECT — FDA accelerated approval for Genmab’s bi-specific ...
艾伯维/Genmab：递交CD3/CD20双抗上市申请 Armstrong 2022年10月28日，艾伯维与 Genmab 宣布递交CD3 ...
Oncology Drug Reference Sheet: Epcoritamab-Bysp | Oncology Nursing Society
CD20/CD3双特异性抗体Epcoritamab治疗复发/难治性LBCL/DLBCL向FDA提交上市申请 - 知乎
Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific ...
